Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis? - Wikidata - wikimedia - TriplyDB

Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?

Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?

http://www.wikidata.org/entity/Q37146567

about

HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial Decoding HIV resistance: from genotype to therapy.The fourth generation AlereTM HIV Combo rapid test improves detection of acute infection in MTN-003 (VOICE) samples.Preexposure prophylaxis for men who have sex with men and transgender persons in early adopting countries: a narrative review.PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection.Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT.Nanoparticle Encapsulation for Antiretroviral Pre-Exposure Prophylaxis.

P2860

Q33848307-13B9732F-AC07-4F6D-8465-FDA30954E593 Q38632663-805E13AF-FCEF-447C-A273-6E3A845641A5 Q38849660-A92A8150-8A46-4483-8E9E-F813D09C63D4 Q40073013-A04F06D0-A26C-47A5-9E56-F5861EA24BBE Q40126361-03BE8197-A0A7-4CD5-8117-D9DBED7BEE7E Q40281007-0E8ECF81-4287-40BF-85A0-12F9B8E72138 Q55338133-711801AD-C44A-4B2E-B982-B87A94E3D15E

P2860

Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?

http://www.wikidata.org/entity/Q37146567

description

2016 թվականի հունվարին հրատարակված գիտական հոդված

@hy

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

name

Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?

@en

Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?

@nl

type

label

Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?

@en

Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?

@nl

prefLabel

Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?

@en

Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?

@nl

P1433

Q37146567-1F95EC41-22D6-4ECC-A577-AE4F50C8E279

P1476

Q37146567-1B397A27-F6D1-4994-8931-CB9658776C5B

P2093

Q37146567-2221D728-E5A7-4AF7-AF2F-9F9617FE8C76

Q37146567-61B5C5D3-0198-43F2-9814-3AB217609A36

P2860

Q37146567-03DACFB7-CF25-4289-A095-687BBDA95B5B

Q37146567-0A8DC8C9-8F8A-46FC-994C-717D17DCF63B

Q37146567-0DD2FAA7-1153-420C-B36A-F1CD92558EE9

Q37146567-0DE12CF2-1C06-48A8-A6F1-9747838CAA45

Q37146567-15079840-E03B-44AF-B5DF-1CA1F2D6E9D8

Q37146567-183F4C7F-AAAA-4AE3-9688-E2E649D1309B

Q37146567-20750A6F-F944-4ECC-9C7A-15526E22EF52

Q37146567-219F54C0-FE68-4FE2-80DA-27631573E20D

Q37146567-22FA2936-B1F1-4FAD-9CDE-61DD581E9C31

Q37146567-286038FD-26CB-4A24-BF5B-376C934FD435

P304

Q37146567-7A197446-A627-40F0-86EF-57BAB0E42A75

P31

Q37146567-530E9326-46D6-4466-90AA-0C7AAE2DDBA7

P356

Q37146567-AF97D5E9-3090-4D86-B0D5-72C4A7A58FAA

P433

Q37146567-5E2B66FE-42A9-4B23-BCBA-F2237F47B725

P478

Q37146567-44DCD1B9-D2AE-4777-B97D-FCE792FEE019

P577

Q37146567-24B4A8FC-B913-4F4D-B920-709073A8BE12

P698

Q37146567-74B2DC9B-4508-4B52-8BD2-207A18709D68

P932

Q37146567-BB2F33BE-5E10-4BFB-B912-C77AA5B224B1

P356

COH.0000000000000209

P1433

Current Opinion in HIV and AIDS

P1476

Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?

@en

P2093

John W Mellors

http://www.w3.org/2001/XMLSchema#string

Urvi M Parikh

http://www.w3.org/2001/XMLSchema#string

P2860

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women

Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial

Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP)

Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009)

Cost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling study

High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa

Preexposure prophylaxis for HIV infection among African women

P304

49-55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/COH.0000000000000209

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26633640

http://www.w3.org/2001/XMLSchema#string

P932

4970748

http://www.w3.org/2001/XMLSchema#string